Elevance Health Inc. (ELV) Stock Analysis
Is ELV a good investment?
Elevance Health Inc. (ELV) has a Plutrex AI rating of 42.0/100 as of October 06, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: Balance sheet fortress: $37.5B cash and $6.3B FCF with D/E of 0.68 provide solvency protection and capital return capacity even during earnings stress. Main concern: Catastrophic growth deficit vs. peers: 5-year forward EPS CAGR of 3.81% is 75% below industry average of 15.33%; historical earnings growth of -13.1% vs. peers' +63.5% — this structural divergence disqualifies ELV from peer-comparable valuations and suggests secular competitive disadvantage in Medicare Advantage and commercial enrollment.
Investment Summary
ELV at $394.51 is a fundamentally challenged managed care company trading at a significant valuation premium despite deteriorating earnings. The investment case is largely negative: PEG of 4.60 vs. industry average of 1.92 (140% premium on growth-adjusted basis) exposes severe overvaluation. Earnings declined -13.1% YoY and EPS fell -10.3% while peers grew earnings +63.5% — a 76.6 percentage point gap. Net margin of 2.5% and operating margin of 4.6% leave virtually no cushion for medical cost inflation. The 5-year forward EPS CAGR of only 3.81% vs. industry average of 15.33% signals structural competitive disadvantage. On the positive side, $37.5B in cash, $6.3B in FCF, and D/E of 0.68 provide balance sheet stability. News is mildly constructive — ELV reaffirmed FY26 EPS guidance ahead of investor meetings (headline: 'Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation'), and institutional re-entry (Baron Health Care Fund Q2 2026 Portfolio Activity) suggests some value-oriented investors see a floor, but these are stabilization signals, not growth catalysts. Analyst consensus target of $443.70 implies 12.5% upside, but this is insufficient compensation given the fundamental deterioration and growth deficit vs. peers.
Key Strengths
- Balance sheet fortress: $37.5B cash and $6.3B FCF with D/E of 0.68 provide solvency protection and capital return capacity even during earnings stress
- Relative profitability edge vs. peers: Net margin 2.47% (+59.7% above industry 1.55%) and ROE 11.2% (+23.3% above industry 9.08%) demonstrate ELV retains above-average capital efficiency
- FY26 EPS guidance reaffirmation ahead of investor meetings (headline: 'Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation') reduces near-term earnings surprise risk and signals management confidence, while institutional re-entry by value-oriented Baron Health Care Fund suggests a perceived valuation floor
Key Concerns
- Catastrophic growth deficit vs. peers: 5-year forward EPS CAGR of 3.81% is 75% below industry average of 15.33%; historical earnings growth of -13.1% vs. peers' +63.5% — this structural divergence disqualifies ELV from peer-comparable valuations and suggests secular competitive disadvantage in Medicare Advantage and commercial enrollment
- Severe growth-adjusted overvaluation: PEG of 4.60 is 140% above the industry average of 1.92; even at next-year growth of 8.86%, implied PEG of ~1.97 still exceeds industry norms; a PEG-normalized fair value implies intrinsic value of $160-$180, representing 55-60% downside from current price of $394.51
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ELV's fundamentals present a bifurcated picture. Balance sheet strength is real: $37.5B cash, $6.3B FCF, D/E of 0.68 (vs. industry 0.746) — these provide solvency protection. ROE of 11.2% exceeds the industry average of 9.08% (+23.3%), and net margin of 2.47% beats the sector average of 1.55% (+59.7%). However, the earnings trajectory is alarming: revenue grew only 1.4% vs. industry 5.06%, earnings collapsed -13.1% YoY vs. industry +63.5%, and EPS fell -10.3%. Operating margin of 4.6% is just below the industry's 4.73%. Valuation: trailing PE of 17.53x appears moderate but is deceptive — at a 5-year EPS CAGR of 3.81%, the PEG of 4.60 is egregious (vs. industry 1.92). Even using next-year EPS growth of 8.86%, the implied PEG of ~1.97 still exceeds industry norms. A PEG-normalized fair value using peers' 1.92x PEG applied to ELV's 3.81% growth implies a P/E of ~7.3x, translating to roughly $160-$180 intrinsic value — a 55-60% discount to current price. P/B of 1.91 is the least alarming metric. The profitability score of 15/100 and growth score of 10/100 are not hyperbole — they reflect genuine systemic earnings deterioration in a company that is losing competitive ground on the metrics that drive managed care valuations.
News Sentiment
Elevance Health is sending mixed signals to Wall Street — and savvy investors are starting to pay attention. The managed care giant recently reaffirmed its full-year 2026 earnings guidance in a move that sent shares higher, according to the headline 'Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation.' That's a rare piece of good news for a company that has watched its earnings fall more than 13% over the past year while competitors posted gains north of 60%. The guidance reaffirmation, delivered proactively ahead of a series of investor meetings, signals that management is trying to draw a line in the sand and restore confidence. On the institutional side, the Baron Health Care Fund's Q2 2026 Portfolio Activity shows that value-oriented money managers are quietly re-establishing positions in ELV — a sign that some professional investors believe the worst may be priced in. Meanwhile, ELV is pushing forward with its Medicare Advantage strategy, with affiliated 2027 plans advancing stability according to a recent filing. But the bigger picture remains challenging. A comparison piece — 'UnitedHealth vs. Elevance: Which Managed-Care Stock Is a Better Buy?' — highlights the competitive pressure ELV faces from larger, faster-growing rivals. The bottom line: ELV is stabilizing, not accelerating. For everyday investors, that means the stock may stop falling but probably won't surge until the company closes its massive growth gap with industry peers.
Risk Assessment
Primary risk for bulls: Medical cost inflation continues to compress the 2.5% net margin toward zero or negative, triggering a multiple de-rating on top of already declining earnings. At the 5-year CAGR of 3.81%, ELV cannot grow into its current 17.53x PE without sustained margin recovery — and the industry backdrop (Medicare Advantage rate pressure, Medicaid redeterminations) makes this difficult. Secondary risk: competitors with 15.33% 5-year EPS growth (UnitedHealth, CVS, Centene peers) continue gaining share, widening the already catastrophic 75% growth gap. Tail risk: regulatory changes to Medicare Advantage reimbursement rates or CMS payment structures could further impair the government segment ELV is doubling down on (headline: 'Elevance Health's Affiliated 2027 Medicare Advantage Plans Advance Stability'). Mitigation for existing holders: $6.3B FCF supports dividends and buybacks as a partial return cushion. For new entrants, the $290-$320 entry zone targets a PE closer to 12-13x on normalized earnings, reducing valuation risk while providing a stop at $345 (below current price) to limit loss if entering on weakness.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ELV a halal stock?
No, Elevance Health Inc. (ELV) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ELV?
Elevance Health Inc. (ELV) has a Plutrex AI rating of 42.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ELV a good investment?
According to Plutrex AI, ELV has a Sell rating (42.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ELV?
US stocks like ELV can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ELV?
Plutrex AI identifies the main risks for ELV by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.